iBio Inc. [AMEX: IBIO] loss -17.78% on the last trading session, reaching $0.45 price per share at the time. The company report on December 9, 2022 that iBio Announces Closing of $3.5 Million Underwritten Public Offering.
In connection with the offering, the Company granted the underwriter a 30-day option to purchase 504,807 additional shares of its common stock and/or warrants to purchase up to 1,009,614 additional shares of its common stock at the public offering price, less underwriting discounts and commissions, which the underwriter partially exercised on December 8, 2022 with respect to the warrants to purchase up to 1,009,614 additional shares of common stock.
iBio Inc. represents 8.84 million in outstanding shares, while the company has a total market value of $4.11 million with the latest information. IBIO stock price has been found in the range of $0.36 to $0.58.
If compared to the average trading volume of 245.67K shares, IBIO reached a trading volume of 2787634 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about iBio Inc. [IBIO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IBIO shares is $3.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IBIO stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JMP Securities have made an estimate for iBio Inc. shares, keeping their opinion on the stock as Mkt Outperform, with their previous recommendation back on November 29, 2021. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on January 22, 2021, representing the official price target for iBio Inc. stock. Previously, the target price had yet another raise to $2.55, while Alliance Global Partners analysts kept a Buy rating on IBIO stock.
The Average True Range (ATR) for iBio Inc. is set at 0.16, with the Price to Sales ratio for IBIO stock in the period of the last 12 months amounting to 1.87. The Price to Book ratio for the last quarter was 0.08, with the Price to Cash per share for the same quarter was set at 1.93.
Trading performance analysis for IBIO stock
iBio Inc. [IBIO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -27.06. With this latest performance, IBIO shares dropped by -74.16% in over the last four-week period, additionally sinking by -93.68% over the last 6 months – not to mention a drop of -97.13% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IBIO stock in for the last two-week period is set at 19.64, with the RSI for the last a single of trading hit 14.07, and the three-weeks RSI is set at 25.09 for iBio Inc. [IBIO]. The present Moving Average for the last 50 days of trading for this stock 1.7892, while it was recorded at 0.5560 for the last single week of trading, and 6.0670 for the last 200 days.
iBio Inc. [IBIO]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and iBio Inc. [IBIO] shares currently have an operating margin of -2085.19 and a Gross Margin at -43.01. iBio Inc.’s Net Margin is presently recorded at -2110.91.
Return on Equity for this stock declined to -58.47, with Return on Assets sitting at -40.83.
iBio Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 2.00.
An analysis of insider ownership at iBio Inc. [IBIO]
There are presently around $1 million, or 13.10% of IBIO stock, in the hands of institutional investors. The top three institutional holders of IBIO stocks are: VANGUARD GROUP INC with ownership of 475,397, which is approximately 7.507% of the company’s market cap and around 2.20% of the total institutional ownership; PRICE T ROWE ASSOCIATES INC /MD/, holding 322,700 shares of the stock with an approximate value of $0.15 million in IBIO stocks shares; and BLACKROCK INC., currently with $0.12 million in IBIO stock with ownership of nearly 71.676% of the company’s market capitalization.
Positions in iBio Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 16 institutional holders increased their position in iBio Inc. [AMEX:IBIO] by around 487,215 shares. Additionally, 26 investors decreased positions by around 160,577 shares, while 19 investors held positions by with 834,164 shares. The mentioned changes placed institutional holdings at 1,481,956 shares, according to the latest SEC report filing. IBIO stock had 7 new institutional investments in for a total of 19,935 shares, while 15 institutional investors sold positions of 27,482 shares during the same period.